Article
Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
Genetic testing and molecular biomarkers - 1 Jan 2000
Ayad Mona Wagdy, Nafea Dalia
Abstract excerpt
Janus Kinase 2 (JAK2) is a member of a family of four Janus Kinases, 2, and 3 and tyrosine kinase 2. Mutated JAK2 (V617F) has the ability to activate downstream signal transducer and activator of transcription (STAT)-mediated transcription in the absence of the ligand erythropoietin. The autoinhibitory activity of JAK2 is disrupted by the presence of the V617F mutation. Somatic mutation in JAK2 (V617F) gene has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.